Cancer Education
focusing on Specialized Topics of Interest

Taught by the Experts




www.BMLI.com
Overview Faculty & Disclosure Agenda Colorado Convention Center Registration
Live Simulcast Educational Needs Target Audience Learning Objectives CME/CE Credit Information
How do you best manage the vast majority of your NSCLC patients?
The New Frontier in NSCLC - Beyond EGFR, VEGF, and ALK: Expanding the paradigm to include patients without actionable mutations
6:00AM Breakfast and Registration
7:00AM Welcome and CME/CE Pre Test
Mark A. Socinski, MD
7:05AM Identifying NSCLC patients without actionable mutations for therapy: How do we use novel genomic and traditional biologic analyses to devise optimal treatment? .
Gregory J. Riely, MD, PhD
7:20AM Relapsed NSCLC: How can we combine angiogenesis inhibition and chemotherapy to improve survival across all histologic subtypes?
Mark A. Socinski, MD
7:35AM Immunotherapy for NSCLC: Does histology or mutation status matter?
Roy S. Herbst, MD, PhD
7:50AM Interactive Panel Discussion and Audience Q & A
Faculty
7:55AM Closing Remarks and CME/CE Post Test
Roy S. Herbst, MD, PhD
8:00AM Adjourn
Overview Back to top
Co-Chairs: Drs. Mark Socinski & Roy S. Herbst

The primary objective is to provide the target audience of oncologists, hematologist/oncologists, and other clinicians with practical knowledge and competence that helps them implement practice performance changes so that they can improve survival in their lung cancer patients with squamous Non-Small Cell Lung Cancer (NSCLC), and/or without actionable mutations.

This activity is aimed at addressing the Practice Gaps corresponding to the unmet medical needs of a very large number of NSCLC patients. This group is approaching 80% of NSCLC patients. These are NSCLC patients with locally advanced or metastatic disease whose malignancy is squamous cell carcinoma and/or is without an identified actionable mutation, which may be of any histology. The patients also include EGFR wild type NSCLC.

For more than 20 years, no new therapeutic options have been available for addressing Practice Gaps to improve outcome for lung cancer patients with squamous cell carcinoma or without identified mutations. Therapy for these NSCLC patients has traditionally consisted of non-targeted approaches. However, investigational strategies with targeted therapy, immuno-oncology and novel chemotherapeutic interventions that demonstrate improved survival and outcome are in late-stage clinical development. Some have already been approved in 2015 and other agents and strategies are expected to become commercially available in the near future.

Bring your own Smartphones, Tablets, or Laptops
(iPad, Android, iPhone, etc.): This will enable participants to use their personal "smart devices" during the symposium to ask and answer all questions of the faculty.

This activity is being hosted in association with
Faculty Information Back to top
Mark A. Socinski, MD (Co-Chair)
Professor of Medicine and Thoracic Surgery
Director, Lung Cancer Section
Division of Hematology/Oncology
Co-Director, UPMC Lung Cancer center of Excellence
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh
UPMC Cancer Pavilion
Pittsburgh, PA

Fees for Non-CME/CE Services Received Directly from Commerical Interest or Their Agents (e.g. speakers’ bureaus): Genentech, Celgene
Contracted Research: Genentech, Celgene, AstraZeneca, Synta, BIND, Aveo, Pfizer, Clovis, Lilly
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Roy S. Herbst, MD, PhD (Co-Chair)
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Translational Research Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT

Consulting Fees: Eli Lilly, Genentech/Roche, Merck, Pfizer
Contracted Research: Genentech
Scientific Advisory Boards: Biothera, Diatech, Kolltan, N of 1

Gregory J. Riely, MD, PhD
Medical Oncologist
Thoracic Oncology Service
Vice Chair,
Clinical Trials Office
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY

Consulting Fees: Novartis
Contracted Research: Pfizer, Infinity, Novartis, Astellas, Roche, Millennium

LEAD NURSE PLANNER
Diane D. DePew, DSN, RN-BC

I have no real or apparent conflicts of interest to report.

PLANNER & CME/CE REVIEWER
Steve Madison, RPh, MBA (BMLI Manager)

I have no real or apparent conflicts of interest to report.

CME/CE PEER REVIEWER
Danielle Shafer, MD

I have no real or apparent conflicts of interest to report.

Supported by an Educational Grant from Celgene
Educational Needs Back to top

Mutations in EGF receptor, the ALK rearrangement, and VEGF receptors are the common actionable proteins in lung carcinoma for targeted therapy. While these alterations are found in adenocarcinomas, and with higher frequencies among certain subpopulations of adenocarcinoma such as never smokers, females and Asians, more than half of lung adenocarcinomas have no known actionable or driver mutation. In squamous lung carcinomas actionable mutations are nearly absent, with a prevalence of only about 3 percent. Most NSCLC is either squamous or adenocarcinoma. Thus, between 70 and 90 percent of all NSCLC patients are not associated with an actionable, driver mutation and this poses a problem to clinicians for devising strategies for their NSCLC patients with this biology. And while year after year new, targeted strategies have emerged for NSCLC with EGFR, ALK and VEGFR, oncologists today face the problem of how to best devise systemic therapies for most of their NSCLC patients without validated biomarkers to guide their decisions. The lack of widespread awareness of recent and emerging strategies to help improve outcome for a large number of NSCLC patients with this biologic characterization is a Practice Gap.

Squamous cell lung carcinoma is a significant unmet medical need. The prognosis for patients with advanced stage squamous NSCLC is dismal. Squamous cell carcinoma is the second largest subgroup of NSCLC. And squamous NSCLC accounts for about 25 to 30 percent of all lung cancers. Five-year survival for this group of NSCLC patients is less than 5 percent. All patients with advanced or metastatic NSCLC either relapse or die. More than 60,000 patients die in the US each year from squamous NSCLC, which is more than the annual deaths from breast cancer and colon cancer combined.

Unquestionably, squamous lung carcinoma, NSCLC patients without actionable mutations, and NSCLC patients who are refractory to initial systemic therapy represent a significant public health problem. For many of these patients chemotherapy is the main systemic therapy option and the role of chemotherapy is not to be underestimated. However, opportunities for new therapies and strategies are needed. Indeed, a number of different therapeutic approaches for patients with squamous NSCLC have been emerging in late-stage clinical development and include strategies involving immune therapy, targeting EGFR, and targeting VEGF/ inhibiting angiogenesis.

Target Audience Back to top

The target audience for this symposium on managing NSCLC patients without actionable mutations includes medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, Fellows, Physician Assistants, oncology nurses/Nurse Practitioners, oncology pharmacists, and other allied health-care professionals involved in the treatment, care and management of patients with NSCLC. Lung cancer is treated optimally by a multi-disciplinary approach and, thus, all of the aforementioned clinician specialties are invited to participate in this symposium.

The BioMedical Learning Institute (BMLI) maintains three separate accreditations: ACCME, ANCC and ACPE, to provide CME for physicians, CNE for nurses and CPE for pharmacists. Other clinical specialties can also earn credit as described below.

  • Physicians can earn CME credit: 1 AMA PRA Category 1 Credit™.
  • Nurses and Nurse Practitioners can earn CNE credit: 1 contact hour
  • Pharmacists can earn CPE credit: 1 contact hour or .1 CEU
  • Physician Assistants can use Certificates of Attendance from BMLI for 1 hour Category 1 Credit from AOACCME
  • Fellows can use Certificates of Attendance from BMLI for 1 hour Credit

Learning Objectives Back to top

Based on the data identified in the Practice Gap Identification and Analysis of this Needs Assessment, the following Learning Objectives have been developed for these CME/CE activities. Separate learning objectives have been developed for physicians, nurses and pharmacists because their roles in addressing unmet medical needs of patients with squamous NSCLC are significantly different.

PHYSICIANS
  1. Analyze how molecular and genomic characteristics of squamous cell lung carcinoma and NSCLC without actionable mutations help guide therapy decisions.
  2. Compare and contrast current and emerging strategies for relapsed NSCLC patients.
  3. Critically assess the clinical data involving novel induction and maintenance strategies for squamous NSCLC.
  4. Evaluate the role of immune therapy for NSCLC patients regardless of histology and mutation status.
NURSES
  1. Describe how molecular and genomic characteristics of squamous cell lung carcinoma and NSCLC without actionable mutations help guide therapy decisions.
  2. List current and emerging strategies for relapsed NSCLC patients.
  3. Recall the clinical data involving novel induction and maintenance strategies for squamous NSCLC.
  4. Describe the role of immune therapy for NSCLC patients regardless of histology and mutation status.
PHARMACISTS
  1. Describe how molecular and genomic characteristics of squamous cell lung carcinoma and NSCLC without actionable mutations help guide therapy decisions.
  2. List current and emerging strategies for relapsed NSCLC patients.
  3. Recall the clinical data involving novel induction and maintenance strategies for squamous NSCLC.
  4. Describe the role of immune therapy for NSCLC patients regardless of histology and mutation status.
CME/CE Credit Information Back to top

Physicians

The BioMedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The BioMedical Learning Institute designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists

The BioMedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-15-003-L01-P
Credits: 1 hour (0.1 ceu)
Type of Activity: Knowledge

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Nurses

The BioMedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The BioMedical Learning Institute designates this educational activity for 1 contact hour.

Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Other

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 1 hour of Category 1 credit for attending this symposium.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.

Colorado Convention Center Back to top

Colorado Convention Center
Rooms: Mile High 2 + 3
700 14th St
Denver, CO 80202
Phone: (303) 228-8000

Live Internet Simulcast Back to top

The following are the instructions on how to participate in the symposium: The New Frontier in NSCLC Beyond EGFR, VEGF, and ALK: Expanding the paradigm to include patients without actionable mutations.  We hope you find this program highly educational and enjoyable.

Options for your participation in the Internet Simulcast
You have 2 ways to participate in this symposium via the Internet Simulcast. Either way will enable you to CME/CE credit.

  • Interactive: One involves interactive participation enabling you ask questions of the faculty just like the participants in the live meeting in Chicago, and to interact with the program and answer clinical and case study questions during each presentation.
  • Non-Interactive: The other way to participate is to watch and listen to the symposium without the ability to ask or answer questions.

If you choose interactive participation for the symposium you will need to have 2 separate internet browser windows open. One browser window is to view and hear the symposium presentations, and the other is to ask and answer questions during the symposium. Each browser window connects to a different Web Site.

You can do this any of a number of ways including having 2 browser windows open on one large computer screen or use your iPhone or iPad or other smart device as your second browser window to answer and ask questions and your computer browser window to view and listen to the symposium.

To connect to view and listen to the symposium in a non-interactive manner please click on the following Web Site hyperlink: http://www.liveeventstream.com/bmli/bmli_09082015.html

To connect to the second Web Site which enables you to ask and answer questions please click on the following Web Site hyperlink with your other browser window or iPad, iPhone, etc.: https://wclc.cnf.io

Technical Requirements and Testing Your Connections  

It is highly recommended you test your connection(s) between 6:00AM to 7:00AM Mountain Time. Our system will be operational during this 60 minute time period which has been dedicated for testing and if you have any questions during this time please use the support chat feature (link to right Web Site) or call the following telephone number: 1-800-209-1868

Minimum Requirements for the Live Internet Simulcast
PC Requirements

You need Windows XP Service Pack 2, Windows Vista, Windows 7 or Windows 8, and you'll need to use Internet Explorer or Firefox for your web browser. You should have at least a 1.2-gigahertz processor and 512 megabytes of RAM. Your Internet connection speed should be at least 1.5 Mbps.

Mac Requirements

You need an Intel-based computer with at least OS 10.4.11 and Firefox 3 or Safari 3. You'll also need at least 1 gigabyte of RAM. Your Internet connection speed should be at least 1.5 Mbps. The Microsoft Silverlight plug-in will be required (it is generally installed on most computers already). You can check here if you have it installed: https://www.microsoft.com/getsilverlight/Get-Started/Install/Default.aspx

Faculty Disclosures of Conflicts of Interest

The attached document contains a list of faculty, BMLI staff members, and other healthcare professionals who have reported real or apparent conflicts of interest (COIs).  According to the ACCME, ACPE and ANCC, COIs are any "relevant financial relationships with commercial supporters" of this symposium.  For your information, all of the conflicts of interest have all been resolved through a rigorous ACCME, ACPE and ANCC-approved peer-review process prior to the symposium.  Please review this faculty disclosure COI document carefully prior to your participation in this symposium.

Symposium Sessions

The scientific sessions of the symposium on Tuesday, September 8, 2015 are scheduled from at 7:00 a.m. to 8:00 a.m mountain time.  The agenda is contained in the enclosed attachment.

Slides, Presentations and Other Archived Materials Slides, all presentations and other archived materials (all panel discussions and Q & A sessions) from this symposium will be posted on the www.BMLI.com Web site in approximately 6 weeks.

CME, CE Certificates, Certificates of Attendance and Completed Symposium Evaluation Forms

You will receive your CME or CE Certificate, or Certificate of Attendance approximately 4 to 6 weeks following the symposium. To receive any of these certificates, participants are required by the ACCME and ACPE to complete the Evaluation Form and then to submit the completed Evaluation Form using your iPad or smart device. To receive CE contact hour credit attendance at the entire activity and the successful completion of the post-test and evaluation form is required. By completing the Evaluation Form, participants are documenting their attendance and claiming their number of CME/CE credit hours. Fellows may complete a Certificate of Attendance for use in seeking CE credit in their States.

This presentation was approved by the 16th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the 16th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by IASLC.